Dr Simon Gibbs is Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London and Lead Clinician and honorary Consultant Cardiologist for the National Pulmonary Hypertension Service at Hammersmith Hospital.
Dr Gibbs trained in medicine at Christ’s College, Cambridge and St Thomas’s Hospital Medical School where he qualified in 1979. His MD thesis on the pulmonary circulation in heart failure was awarded in 1993 by the University of Cambridge for work undertaken at the National Heart Hospital with Professor Kim Fox and the late Professor Philip Poole-Wilson
Dr Gibbs trained in cardiology in London and was appointed to his current position within NHLI in February 1997, after having served as a Consultant in Cardiology and General Medicine at Bromley Hospital and the Royal Brompton Hospital, London. Since then he has developed and grown the Pulmonary Hypertension Service at Hammersmith Hospital which is now a thriving clinical service focused on obtaining best outcomes for patients through high quality clinical research and audit.
The clinical research programme specifically focuses on the failing right ventricle, developing end points for clinical trials in pulmonary hypertension, conducting in-house Phase II trials of novel agents for treating pulmonary arterial hypertension, and vasculopathy in sickle cell disease. Additional studies have investigated the pulmonary circulation at high altitude both in the high alps and in a barochamber. Over the last few years this programme has been funded by the British Heart Foundation, the Medical Research Council and the National Institutes of Health (USA). It has been conducted in collaboration with Professor Martin Wilkins in Clinical Pharmacology and colleagues in Europe and the USA.
Dr Gibbs was a member of a small group of clinicians who obtained national designation for the Hammersmith service and five other clinical services in England in 2001. He has since chaired the Physicians Committee of the Pulmonary Hypertension Service for the UK and Ireland for 3 years, and is now Lead Clinician for the National Audit of Pulmonary Hypertension, chairman of its Project Board and its Pulmonary Hypertension Outcomes Group. He is a member of the Clinical Reference Group for Pulmonary Hypertension. He hosts an annual international masterclass on pulmonary hypertension. In the past he was a member of the Department of Health External Reference Group on Standards in Adult Congenital Heart Disease, and the Chief Medical Officer’s independent expert working group on the prevention of venous thromboembolism in hospitalised patients.
He has participated in task forces at the World Symposia on Pulmonary Hypertension, UK, European and American guidelines task forces in pulmonary hypertension, pulmonary embolism, pregnancy in heart disease and emergency oxygen, international pulmonary hypertension clinical trial steering committees and end points adjudication committees. He has also served as an Expert European Scientific Advisor to the European Medicines Agency, and as a member of the Executive Committee of the International Society of Mountain Medicine. He has made presentations to congresses and societies across the UK, Europe, North America and Asia.
Dr Gibbs is Past Chairman of the Working Group on the Pulmonary Circulation and Right Ventricle at the European Society of Cardiology, and co-chairman of the left heart disease and pulmonary hypertension task force of the International Society of Heart & Lung Transplantation. He was elected a Fellow of the European Society of Cardiology in 2009.
et al., 2017, Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study, Radiology, Vol:283, ISSN:0033-8419, Pages:381-390
et al., 2017, Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model, European Respiratory Journal, Vol:50, ISSN:0903-1936
et al., 2017, BTS guideline for oxygen use in adults in healthcare and emergency settings, Thorax, Vol:72, ISSN:0040-6376
et al., 2017, Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years, British Journal of Surgery, Vol:104, ISSN:0007-1323, Pages:166-178
et al., 2017, Rationale And Design Of The Replace Trial: Riociguat Replacing Phosphodiesterase 5 Inhibitor (pde5i) Therapy Evaluated Against Continued Pde5i Therapy In Patients With Pulmonary Arterial Hypertension (pah), International Conference of the American-Thoracic-Society (ATS), AMER THORACIC SOC, ISSN:1073-449X